Fidelis Capital Partners’s Edwards Lifesciences EW Stock Holding History

Fidelis Capital Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$340K	Buy	4,247 +102	+2%	+$8.41K	0.02%	379
2025 Q4	$353K	Buy	4,145 +63	+2%	+$5.17K	0.03%	371
2025 Q3	$317K	Buy	4,082 +12	+0.3%	+$938	0.02%	378
2025 Q2	$320K	Buy	4,070 +469	+13%	+$35K	0.03%	335
2025 Q1	$274K	Sell	3,601 -362	-9%	-$25.9K	0.03%	336
2024 Q4	$283K	Sell	3,963 -580	-13%	-$40.6K	0.03%	346
2024 Q3	$321K	Sell	4,543 -1,028	-18%	-$74.7K	0.04%	306
2024 Q2	$340K	Buy	5,571 +507	+10%	+$44.9K	0.05%	262
2024 Q1	$484K	Buy	5,064 +690	+16%	+$58K	0.07%	214
2023 Q4	$334K	Buy	4,374 +586	+15%	+$40.8K	0.07%	230
2023 Q3	$262K	Sell	3,788 -677	-15%	-$54.4K	0.09%	217
2023 Q2	$421K	Buy	4,465 +233	+6%	+$20.3K	0.15%	151
2023 Q1	$376K	Buy	+4,232	New	+$333K	0.16%	147

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelis Capital Partners's EW Position: Q1 2026 in Review

Fidelis Capital Partners increased its Edwards Lifesciences (EW) stake by 2.5% in Q1 2026, buying an estimated $8.41K and bringing the position to 4,247 shares worth $340K. The position accounts for 0.02% of the portfolio, ranked #379.

Fidelis Capital Partners first reported a position in EW in Q1 2023 and has held it in 13 quarters since. The position peaked at $484K in Q1 2024. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Fidelis Capital Partners held 4,247 shares of Edwards Lifesciences worth $340K as of Q1 2026.
Fidelis Capital Partners bought 102 Edwards Lifesciences shares in Q1 2026, an estimated $8.41K.
Edwards Lifesciences made up 0.02% of Fidelis Capital Partners's portfolio in Q1 2026, its #379 holding.
Fidelis Capital Partners first reported a position in Edwards Lifesciences in Q1 2023 and has held it in 13 quarters since.
Fidelis Capital Partners's Edwards Lifesciences position peaked at $484K in Q1 2024.
1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Fidelis Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.